Abstract
<div>AbstractPurpose:<p><i>EGFR</i> exon 20 insertions (ex20ins) are an uncommon genotype in non–small cell lung cancer (NSCLC) for which targeted therapies are under development. We sought to describe treatment outcomes and genomic and immunophenotypic characteristics of these tumors.</p>Experimental Design:<p>We identified sequential patients with NSCLC with <i>EGFR</i> ex20ins and compared their clinical outcomes and pathologic features with other patients with NSCLC.</p>Results:<p>Among 6,290 patients with NSCLC, 106 (2%) had <i>EGFR</i> ex20ins. Patients with <i>EGFR</i> ex20ins were more likely to be Black (14% vs. 6%; <i>P</i> < 0.001) or Asian (22% vs. 10%; <i>P</i> < 0.001) compared with all other patients with NSCLC. Median tumor mutational burden (TMB; 3.5 vs. 5.9; <i>P</i> < 0.001) and proportion of tumors with PD-L1 expression ≥1% (22% vs. 60%; <i>P</i> < 0.001) were lower in <i>EGFR</i> ex20ins compared with other NSCLCs (TMB, <i>n</i> = 5,851 and PD-L1 expression, <i>n</i> = 282) and <i>EGFR</i> del 19/L858R (median TMB, 3.5; <i>P</i> = 0.001 and 39% PD-L1 ≥ 1%; <i>P</i> = 0.02). Compared with a 2:1 cohort of patients with metastatic NSCLC without targetable alterations (<i>n</i> = 192), <i>EGFR</i> ex20ins patients had longer overall survival (median 20 vs. 12 months; HR, 0.56; <i>P</i> = 0.007) and longer time to treatment discontinuation (TTD) for platinum chemotherapy (median, 7 vs. 4 months; HR, 0.6; <i>P</i> = 0.02) and no improvement in TTD for immune checkpoint inhibitors (ICI; HR, 1.75; <i>P</i> = 0.05).</p>Conclusions:<p>With better outcomes on platinum chemotherapy, patients with <i>EGFR</i> ex20ins NSCLC have improved prognosis, lower PD-L1 expression and TMB, and derive less benefit from ICIs compared with patients with NSCLC without targetable oncogenes. Improving molecularly targeted therapies could provide greater benefit for patients with <i>EGFR</i> ex20ins.</p></div>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
